Thanos Mourikis

Thanos Mourikis

Auto-generated profile, based on publicly available information

Thanos Mourikis

Novartis Biomedical Research, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
ECEmilie A. Chapeau
Emilie A. Chapeau
LSLaurent Sansregret
Laurent Sansregret
GGGiorgio G. Galli
Giorgio G. Galli
PCPatrick Chène
Patrick Chène
MWMarkus Wartmann
Markus Wartmann
TSTobias Schmelzle
Tobias Schmelzle
The YAP–TEAD protein–protein interaction mediates YAP oncogenic functions downstream of the Hippo pathway. To date, available YAP–TEAD pharmacologic agents bind into the lipid pocket of TEAD, targeting the interaction indirectly via allosteric changes. However, the consequences of a direct pharmacological disruption of the interface between YAP and TEADs remain largely unexplored. Here, we present IAG933 and its analogs as potent first-in-class and selective disruptors of the YAP–TEAD protein–protein interaction with suitable properties to enter clinical trials. Pharmacologic abrogation of the interaction with all four TEAD paralogs resulted in YAP eviction from chromatin and reduced Hippo-mediated transcription and induction of cell death. In vivo, deep tumor regression was observed in Hippo-driven mesothelioma xenografts at tolerated doses in animal models as well as in Hippo-altered cancer models outside mesothelioma. Importantly this also extended to larger tumor indications, such as lung, pancreatic and colorectal cancer, in combination with RTK, KRAS-mutant selective and MAPK inhibitors, leading to more efficacious and durable responses. Clinical evaluation of IAG933 is underway.

17 June 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
ECEmilie A. Chapeau
Emilie A. Chapeau
LSLaurent Sansregret
Laurent Sansregret
GGGiorgio G. Galli
Giorgio G. Galli
PCPatrick Chène
Patrick Chène
MWMarkus Wartmann
Markus Wartmann
TSTobias Schmelzle
Tobias Schmelzle

1 June 2025 in Cancer Research Communications
Verified
Journal Article
Open access
LLLang Ho Lee
Lang Ho Lee
XXXin Xu
Xin Xu
TMThanos Mourikis
Thanos Mourikis
FTFanying Tang
Fanying Tang
LFLauren Fairchild
Lauren Fairchild
JWJincheng Wu
Jincheng Wu
Immune checkpoint inhibitors (ICI) have demonstrated clinical efficacy in non–small cell lung cancer (NSCLC), and extensive research has been conducted to explore biomarkers predictive of ICI response. However, the impact of ICI on the tumor and tumor microenvironment at primary and acquired resistance states is understudied due to the difficulty of collecting tissue biopsies at disease progression. In this study, we leveraged clinical and real-world data to study ICI resistance. Data used in this work consist of treatment outcome information and tissue RNA sequencing data from advanced-stage NSCLC cohorts from three sources: the Tempus real-world evidence database; CANOPY-1 (NCT03631199), a phase III clinical trial in first-line NSCLC; and Stand Up To Cancer (SU2C) publication. Our results indicate higher IFNγ and T-cell exhaustion in patients’ tumors at acquired resistance and low levels of B-cell and dendritic cell expression at primary resistance. The lower B-cell and dendritic cell levels may be primarily driven by prior treatment with a platinum-based chemotherapy regimen. Baseline transcriptomics data additionally suggest that innate immune cells may play an antitumor role in PD-L1<1% patients, whereas IFNγ and T-cell inflammation are more predictive of ICI treatment outcomes in PD-L1≥1% patients. Our study suggests a clear divergence of the tumor microenvironment in patients with primary versus acquired resistance and a potential role of myeloid cells in the PD-L1<1% population. These findings shed light on potential next-generation therapies to overcome ICI resistance. Significance: ICI benefits patients with NSCLC, but resistance remains common. Our research highlights differences in tumor environments between primary and acquired resistance after ICI treatment, emphasizing distinct post-therapy approaches. Findings also suggest myeloid cells as key players in PD-L1–negative cases, guiding future treatment strategies to overcome resistance and improve outcomes.

30 June 2025
Verified
Other
Open access
PDF file
LLLang Ho Lee
Lang Ho Lee
XXXin Xu
Xin Xu
TMThanos Mourikis
Thanos Mourikis
FTFanying Tang
Fanying Tang
LFLauren Fairchild
Lauren Fairchild
JWJincheng Wu
Jincheng Wu
Immune signature expression (B cell, DC, IFNg pathway and T cell exhaustion) in PD-L1 <1% and PD-L1 1% to 49% treatment naïve and post-ICI samples

30 June 2025
Verified
Other
Open access
LLLang Ho Lee
Lang Ho Lee
XXXin Xu
Xin Xu
TMThanos Mourikis
Thanos Mourikis
FTFanying Tang
Fanying Tang
LFLauren Fairchild
Lauren Fairchild
JWJincheng Wu
Jincheng Wu
Baseline gene expression with significant association with ICI treatment outcome (OS) in PD-L1 negative in both CANOPY-1 and Tempus cohort 1 patients

30 June 2025
Verified
Other
Open access
PDF file
LLLang Ho Lee
Lang Ho Lee
XXXin Xu
Xin Xu
TMThanos Mourikis
Thanos Mourikis
FTFanying Tang
Fanying Tang
LFLauren Fairchild
Lauren Fairchild
JWJincheng Wu
Jincheng Wu
Immune signature expression (B cell, DC, IFNg pathway and T cell exhaustion) by biopsy location and PD-L1 subgroup in unpaired treatment naïve and post-ICI samples